Digene Fights Antitrust Charges As Part Of HPV Diagnostics Patent Case
This article was originally published in The Gray Sheet
Executive Summary
Human papillomavirus test maker Digene, recently acquired by Qiagen, is defending itself against allegations of anti-competitive business practices from Third Wave Technologies as part of a larger patent battle between the firms
You may also be interested in...
Qiagen Monopoly In HPV Test Market Won’t Last, Judge Says
A U.S. district court turned down Third Wave Technologies' claims that Qiagen engages in anti-competitive behavior in the cervical cancer screening space, but the ruling suggests the direction of the market will be in Third Wave's favor
Qiagen Monopoly In HPV Test Market Won’t Last, Judge Says
A U.S. district court turned down Third Wave Technologies' claims that Qiagen engages in anti-competitive behavior in the cervical cancer screening space, but the ruling suggests the direction of the market will be in Third Wave's favor
Qiagen, Ventana settle dispute
Qiagen (formerly Digene) and Ventana Medical settle their dispute over patents related to human papillomavirus tests Dec. 15. Ventana will pay an undisclosed cash amount. Qiagen is involved in ongoing disputes with other HPV test developers Third Wave Technologies and Roche (1"The Gray Sheet" Oct. 22, 2007, p. 22)